Completed PHASE1 INTERVENTIONAL 2-arm NCT01257919

Safety and Pharmacokinetics of Azelaic Acid Foam, 15% in Papulopustular Rosacea

Investigator-blinded, Randomized, Cross-over, Multiple Dose Phase I Study on Safety and Pharmacokinetics of Topically Applied Azelaic Acid Foam, 15% Compared to Azelaic Acid Gel, 15% in Subjects With Papulopustular Rosacea

Sponsor: Bayer

Conditions Papulopustular Rosacea

Interventions Azelaic Acid Foam Azelaic Acid Gel

Updated 8 times since 2017 Last updated: Jun 8, 2023 Started: Jan 31, 2011 Primary completion: Mar 31, 2011 Completion: Mar 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Papulopustular Rosacea, this trial is completed. The trial is conducted by Bayer and has accumulated 8 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jul 2023 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2023 [monthly]

Completed PHASE1
May 2020 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Jun 2018 — May 2020 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jan 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer
LEO Pharma

Data source: LEO Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Las Vegas, United States